JP2023528255A5 - - Google Patents
Info
- Publication number
- JP2023528255A5 JP2023528255A5 JP2022570271A JP2022570271A JP2023528255A5 JP 2023528255 A5 JP2023528255 A5 JP 2023528255A5 JP 2022570271 A JP2022570271 A JP 2022570271A JP 2022570271 A JP2022570271 A JP 2022570271A JP 2023528255 A5 JP2023528255 A5 JP 2023528255A5
- Authority
- JP
- Japan
- Prior art keywords
- tcr
- seq
- polypeptide
- amino acid
- sequence identity
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063026445P | 2020-05-18 | 2020-05-18 | |
| US63/026,445 | 2020-05-18 | ||
| PCT/US2021/032818 WO2021236548A1 (en) | 2020-05-18 | 2021-05-17 | Engineered t cell receptors and methods of use |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2023528255A JP2023528255A (ja) | 2023-07-04 |
| JP2023528255A5 true JP2023528255A5 (enExample) | 2024-05-28 |
| JP7785696B2 JP7785696B2 (ja) | 2025-12-15 |
Family
ID=78708026
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022570271A Active JP7785696B2 (ja) | 2020-05-18 | 2021-05-17 | 操作されたｔ細胞受容体および使用の方法 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20230190812A1 (enExample) |
| EP (1) | EP4153618A4 (enExample) |
| JP (1) | JP7785696B2 (enExample) |
| CN (1) | CN116322715A (enExample) |
| AU (1) | AU2021276264A1 (enExample) |
| CA (1) | CA3183663A1 (enExample) |
| TW (1) | TWI907427B (enExample) |
| WO (1) | WO2021236548A1 (enExample) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3236237A1 (en) * | 2021-10-25 | 2023-05-04 | Board Of Regents, The University Of Texas System | Peptides and engineered t cell receptors targeting mage-a4 antigen and methods of use |
| CN114149978B (zh) * | 2022-02-09 | 2022-04-26 | 深圳博雅感知药业有限公司 | 制备car-t细胞的方法 |
| CN116836261A (zh) * | 2022-03-24 | 2023-10-03 | 香雪生命科学技术（广东）有限公司 | 一种识别mage-a4抗原的高亲和力tcr及其序列和应用 |
| AU2024214482A1 (en) | 2023-02-03 | 2025-08-07 | Zelluna Immunotherapy As | Anti-mage-a4 t cell receptors |
| CN120924527B (zh) * | 2025-10-16 | 2026-02-06 | 内蒙古科为博生物科技有限公司 | 一种内切葡聚糖酶突变体eg06、其编码基因及其产品与应用 |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101773690B1 (ko) * | 2007-03-05 | 2017-08-31 | 인터내셔널 인스티튜트 오브 캔서 이무놀로지 인코퍼레이티드 | 암 항원 특이적 ｔ 세포의 수용체 유전자 및 그것에 따라 코드되는 펩티드 및 이들의 사용 |
| CN102272153B (zh) * | 2008-11-24 | 2015-04-15 | 德国慕尼黑亥姆霍兹研究中心健康和环境有限公司 | 高亲和力t细胞受体及其应用 |
| GB0911566D0 (en) * | 2009-07-03 | 2009-08-12 | Immunocore Ltd | T cell receptors |
| US9803246B2 (en) * | 2011-06-28 | 2017-10-31 | International Institute Of Cancer Immunology, Inc. | Receptor gene for peptide cancer antigen-specific T cell |
| EP3572510B1 (en) * | 2013-11-21 | 2022-09-21 | Repertoire Genesis Incorporation | T cell receptor and b cell receptor repertoire analysis system, and use of same in treatment and diagnosis |
| US11047011B2 (en) * | 2015-09-29 | 2021-06-29 | iRepertoire, Inc. | Immunorepertoire normality assessment method and its use |
| IL308831A (en) * | 2016-04-08 | 2024-01-01 | Immunocore Ltd | T cell receptors |
| MX2020001879A (es) * | 2017-08-18 | 2020-07-29 | Gritstone Oncology Inc | Proteínas de fijación al antígeno que se dirigen a antígenos compartidos. |
| AU2018395397A1 (en) * | 2017-12-28 | 2020-08-06 | Gritstone Bio, Inc. | Antigen-binding proteins targeting shared antigens |
| US20210061876A1 (en) * | 2017-12-29 | 2021-03-04 | Max-Delbrück-Centrum Für Molekulare Medizin In Der Helmholtz-Gemeinschaft | T cell receptors for tumor specific proteasome splice variants and uses thereof |
| KR20200119840A (ko) * | 2018-02-09 | 2020-10-20 | 이매틱스 유에스 인코포레이티드 | T 세포의 제조 방법 |
| DE102018108612A1 (de) * | 2018-03-21 | 2019-09-26 | Immatics US, Inc. | Verfahren zur erhöhung der persistenz von adoptiv infundierten t-zellen |
| US20220213167A1 (en) * | 2019-05-03 | 2022-07-07 | Gigamune, Inc. | Engineered cells expressing anti-tumor t cell receptors and methods of use thereof |
-
2021
- 2021-05-17 EP EP21807947.3A patent/EP4153618A4/en active Pending
- 2021-05-17 US US17/998,914 patent/US20230190812A1/en active Pending
- 2021-05-17 WO PCT/US2021/032818 patent/WO2021236548A1/en not_active Ceased
- 2021-05-17 AU AU2021276264A patent/AU2021276264A1/en active Pending
- 2021-05-17 CN CN202180049915.XA patent/CN116322715A/zh active Pending
- 2021-05-17 CA CA3183663A patent/CA3183663A1/en active Pending
- 2021-05-17 JP JP2022570271A patent/JP7785696B2/ja active Active
- 2021-05-18 TW TW110117938A patent/TWI907427B/zh active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7573441B2 (ja) | ガイダンス及びナビゲーションコントロール蛋白質並びにその生産及び使用方法 | |
| EP2964675B1 (en) | Engager cells for immunotherapy | |
| US7763243B2 (en) | In situ immunization | |
| JP2021042224A (ja) | Ｃｄ−１９を標的とするキメラ抗原受容体 | |
| JP2023548556A5 (enExample) | ||
| CN106397593A (zh) | 抗磷脂酰肌醇蛋白多糖‑3的抗体及其应用 | |
| CN113713091A (zh) | 工程免疫细胞及其用途和生产方法 | |
| KR20210132668A (ko) | 인공 면역감시 키메라 항원 수용체(ai-car) 및 이를 발현하는 세포 | |
| CN117924519A (zh) | 靶向cd138的嵌合抗原受体 | |
| Haas et al. | Bispecific antibodies increase T-cell stimulatory capacity in vitro of human autologous virus-modified tumor vaccine. | |
| JP2023530245A5 (enExample) | ||
| CN111434691A (zh) | Pd-l2单克隆抗体及其应用 | |
| JP2024539273A5 (enExample) | ||
| JP2024526836A5 (enExample) | ||
| WO2024243807A1 (zh) | 靶向ny-eso-1的高亲和力t细胞受体及其应用 | |
| JP2025504883A (ja) | 決定可能な親和性で特定のペプチドを結合する抗原認識コンストラクト、およびｋｒａｓに抗原特異性を有するｔ細胞レセプター、ならびに、対応する核酸配列、ベクター、宿主細胞、医薬組成物、およびキット | |
| WO2024114546A1 (zh) | 抗fgfr4单克隆抗体、靶向fgfr4的嵌合抗原受体t细胞及其应用 | |
| CN120441708A (zh) | 一种靶向cd3和l1cam的双特异性抗体及其应用 | |
| CN118108845A (zh) | 一种靶向B7-H3的CAR-γδT细胞的制备方法及应用 | |
| JP2024517630A5 (enExample) | ||
| HK1219967B (en) | Engager cells for immunotherapy |